HS
BCRX icon

HighVista Strategies’s BioCryst Pharmaceuticals BCRX Stock Holding History

HighVista Strategies’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-68,725
Closed -$484K – 139
2023
Q2 		$484K Buy
+68,725
New +$552K 0.22% 119
2022
Q4 		– Sell
-25,837
Closed -$326K – 107
2022
Q3 		$326K Buy
+25,837
New +$332K 0.19% 92
2021
Q3 		– Sell
-15,316
Closed -$242K – 128
2021
Q2 		$242K Hold
15,316
– – 0.17% 71
2021
Q1 		$156K Sell
15,316
-9,484
-38% -$97.8K 0.12% 83
2020
Q4 		$185K Hold
24,800
– – 0.12% 73
2020
Q3 		$85K Buy
+24,800
New +$106K 0.06% 87

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

HighVista Strategies's BCRX Position: Q3 2023 in Review

HighVista Strategies sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2023, closing a stake of 68,725 shares — an estimated $484K sold.

HighVista Strategies first reported a position in BCRX in Q3 2020 and held it in 6 quarters. The position peaked at $484K in Q2 2023. 233 funds tracked by Wall St. Rank hold BCRX as of Q3 2023.

  • HighVista Strategies reported no remaining BioCryst Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • HighVista Strategies sold 68,725 BioCryst Pharmaceuticals shares in Q3 2023, an estimated $484K.
  • HighVista Strategies first reported a position in BioCryst Pharmaceuticals in Q3 2020 and held it in 6 quarters.
  • HighVista Strategies's BioCryst Pharmaceuticals position peaked at $484K in Q2 2023.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2023.

Based on HighVista Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.